Francesca Ceccherini-Silberstein

List of Publications by Year
in descending order

233 papers	4,773 citations	125106 35 h-index	182931 54 g-index
235 all docs	235 docs citations	235 times ranked	6463 citing authors

#	Article	IF	Citations
1	Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment. Methods, 2022, 201, 74-81.	1.9	8
2	Efficacy of 8 weeks elbasvir/grazoprevir regimen for naÃ¯ve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study. Digestive and Liver Disease, 2022, 54, 1117-1121.	0.4	1
3	Human Monocyte-Derived Macrophages (MDM): Model 1 (GM-CSF). Methods in Molecular Biology, 2022, 2407, 91-96.	0.4	1
4	First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario?. Microorganisms, 2022, 10, 268.	1.6	12
5	Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients. Scientific Reports, 2022, 12, 1374.	1.6	1
6	A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial. Lancet HIV,the, 2022, 9, e79-e90.	2.1	18
7	The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures. Viruses, 2022, 14, 16.	1.5	3
8	Research news in clinical context. Sexually Transmitted Infections, 2022, 98, 159-160.	0.8	0
9	Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines, 2022, 10, 443.	1.4	4
10	External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy. Scientific Reports, 2022, 12, 3291.	1.6	4
11	Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile. Microbiology Spectrum, 2022, 10, e0273221.	1.2	35
12	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports, 2022, 4, 100462.	2.6	10
13	Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches. Infection, Genetics and Evolution, 2022, 101, 105294.	1.0	1
14	Phosphatidylcholine Liposomes Down-Modulate CD4 Expression Reducing HIV Entry in Human Type-1 Macrophages. Frontiers in Immunology, 2022, 13, .	2.2	0
15	Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control. Journal of Antimicrobial Chemotherapy, 2021, 76, 396-412.	1.3	16
16	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. Journal of Hepatology, 2021, 74, 801-810.	1.8	26
17	Virological response and resistance profile in highly treatmentâ€experienced HIVâ€1â€infected patients switching to dolutegravir plus boosted darunavir in clinical practice. HIV Medicine, 2021, 22, 519-525.	1.0	6
18	Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. Journal of Antimicrobial Chemotherapy, 2021, 76, 1277-1285.	1.3	14

#	Article	IF	Citations
19	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3â€infected patients within the Italian network VIRONETâ€C. Liver International, 2021, 41, 1802-1814.	1.9	12
20	Alarming rates of virological failure and HIVâ€1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READYâ€study in Cameroon. HIV Medicine, 2021, 22, 567-580.	1.0	10
21	The impact of DAAâ€mediated HCV eradication on CD4⁺ and CD8⁺ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort. Journal of Viral Hepatitis, 2021, 28, 779-786.	1.0	12
22	Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b. Viruses, 2021, 13, 743.	1.5	2
23	An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. Microorganisms, 2021, 9, 752.	1.6	10
24	HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol. PLoS ONE, 2021, 16, e0253587.	1.1	1
25	Research news in clinical context. Sexually Transmitted Infections, 2021, 97, 321-322.	0.8	0
26	Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study. Viruses, 2021, 13, 1403.	1.5	3
27	SHARED: An International Collaboration to Unravel Hepatitis C Resistance. Viruses, 2021, 13, 1580.	1.5	6
28	Circulating SARS-CoV-2 variants in Italy, October 2020â€“March 2021. Virology Journal, 2021, 18, 168.	1.4	36
29	HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. Biomedicines, 2021, 9, 1352.	1.4	1
30	Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. Journal of Antimicrobial Chemotherapy, 2021, 76, 3272-3279.	1.3	0
31	Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. Gut, 2021, 70, 2337-2348.	6.1	36
32	HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. Open Forum Infectious Diseases, 2021, 8, ofaa566.	0.4	2
33	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. Microbiology Spectrum, 2021, 9, e0109621.	1.2	39
34	Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019. Infezioni in Medicina, 2021, 29, 242-251.	0.7	0
35	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. Journal of Antimicrobial Chemotherapy, 2020, 75, 681-689.	1.3	8
36	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. Journal of Clinical Virology, 2020, 130, 104534.	1.6	11

#	Article	IF	Citations
37	Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. Microorganisms, 2020, 8, 1819.	1.6	7
38	Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. Life, 2020, 10, 302.	1.1	15
39	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. Journal of Antimicrobial Chemotherapy, 2020, 75, 3349-3358.	1.3	13
40	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. Viruses, 2020, 12, 791.	1.5	11
41	Virological characterization of patients with chronic hepatitis C and failure to a glecaprevir/pibrentasvir or voxilaprevir/ velpatasvir/sofosbuvir treatment in the international shared collaboration. Journal of Hepatology, 2020, 73, S107-S108.	1.8	0
42	Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort. Journal of Hepatology, 2020, 73, S343.	1.8	0
43	Cryptic HBV viremia in anti-HBC positive/HBsAg negative patients with HIV infection is frequently revealed by applying an ultrasensitive droplet digital PCR assay. Journal of Hepatology, 2020, 73, S844.	1.8	0
44	Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. Journal of Antimicrobial Chemotherapy, 2020, 75, 1778-1786.	1.3	11
45	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro. Viruses, 2020, 12, 251.	1.5	8
46	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. Journal of Antimicrobial Chemotherapy, 2020, 75, 1026-1030.	1.3	20
47	HIV MDR is still a relevant issue despite its dramatic drop over the years. Journal of Antimicrobial Chemotherapy, 2020, 75, 1301-1310.	1.3	13
48	HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol. Systematic Reviews, 2020, 9, 93.	2.5	4
49	HHV-8 Genetic Diversification and Its Impact on Severe Clinical Presentation of Associated Diseases. Journal of Infectious Diseases, 2020, 222, 1250-1253.	1.9	3
50	Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo , hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. Emerging Microbes and Infections, 2020, 9, 928-939.	3.0	5
51	Research news in clinical context. Sexually Transmitted Infections, 2020, 96, 235-236.	0.8	0
52	Successful ongoing retreatment with glecaprevir/pibrentasvirÂ+ sofosbuvirÂ+ ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance. Clinical Microbiology and Infection, 2020, 26, 1266-1268.	2.8	3
53	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resistance Updates, 2020, 53, 100721.	6.5	80
54	Research news in clinical context. Sexually Transmitted Infections, 2020, 96, 471-472.	0.8	0

#	Article	IF	Citations
55	New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of <scp>HIV</scp>â€1 reverse transcriptase (M184L and M184T). Chemical Biology and Drug Design, 2019, 93, 50-59.	1.5	3
56	THU-134-Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment. Journal of Hepatology, 2019, 70, e219-e220.	1.8	0
57	Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage. Medicina (Lithuania), 2019, 55, 297.	0.8	15
58	NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. Cells, 2019, 8, 666.	1.8	13
59	SAT-196-The integrated use of highly sensitive HBV markers can predict HBV reactivation in HBsAg-negative/Anti-HBc positive patients from oncohematological setting. Journal of Hepatology, 2019, 70, e716.	1.8	0
60	SAT-190-Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection. Journal of Hepatology, 2019, 70, e713-e714.	1.8	0
61	Effectiveness of dolutegravirâ€based regimens as either firstâ€line or switch antiretroviral therapy: data from the Icona cohort. Journal of the International AIDS Society, 2019, 22, e25227.	1.2	46
62	Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. Journal of Clinical Virology, 2019, 117, 61-67.	1.6	24
63	HCV resistance compartmentalization within tumoral and nonâ€tumoral liver in transplanted patients with hepatocellular carcinoma. Liver International, 2019, 39, 1986-1998.	1.9	6
64	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. Journal of Antimicrobial Chemotherapy, 2019, 74, 2732-2741.	1.3	11
65	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. Sexually Transmitted Infections, 2019, 95, 619-625.	0.8	18
66	Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen. Antiviral Therapy, 2019, 24, 321-331.	0.6	4
67	Is the rate of virological failure to cART continuing to decline in recent calendar years?. Journal of Clinical Virology, 2019, 116, 23-28.	1.6	11
68	HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon. BMC Infectious Diseases, 2019, 19, 246.	1.3	14
69	A snapshot of virological presentation and outcome of immunosuppressionâ€driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. Journal of Viral Hepatitis, 2019, 26, 846-855.	1.0	9
70	Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. Virus Genes, 2019, 55, 290-297.	0.7	0
71	Real life experiences in HCV management in 2018. Expert Review of Anti-Infective Therapy, 2019, 17, 117-128.	2.0	8
72	Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 614-617.	1.3	23

#	Article	IF	Citations
73	Evolution of major nonâ€HIVâ€related comorbidities in HIVâ€infected patients in the Italian Cohort of Individuals, NaÃ¯ve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004â€“2014. HIV Medicine, 2019, 20, 99-109.	1.0	19
74	The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stressâ€“Driven Mucus Depletion and Exacerbates Intestinal Inflammation. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 457-473.	2.3	84
75	2019 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 2019, 27, 111-121.	0.1	127
76	Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resistance Updates, 2018, 37, 17-39.	6.5	155
77	Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy. Clinical Gastroenterology and Hepatology, 2018, 16, 977-978.	2.4	12
78	Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 871-881.	1.3	2
79	Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. Medicine (United States), 2018, 97, e0176.	0.4	13
80	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. Journal of Hepatology, 2018, 68, 597-600.	1.8	28
81	The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. Journal of Virus Eradication, 2018, 4, 179-181.	0.3	9
82	Viral resistance in HCV infection. Current Opinion in Virology, 2018, 32, 115-127.	2.6	13
83	Genetic divergence of HIV-1 B subtype in Italy over the years 2003â€“2016 and impact on CTL escape prevalence. Scientific Reports, 2018, 8, 15739.	1.6	2
84	Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors. Applied Microbiology and Biotechnology, 2018, 102, 9925-9936.	1.7	3
85	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. Journal of Antimicrobial Chemotherapy, 2018, 73, 3460-3470.	1.3	8
86	Different kinetics of viral replication and DNA integration in the main HIV-1 cellular reservoirs in the presence and absence of integrase inhibitors. Antiviral Research, 2018, 160, 165-174.	1.9	4
87	HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. Infection, 2018, 46, 717-720.	2.3	2
88	Firstâ€line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison. HIV Medicine, 2018, 19, 475-484.	1.0	13
89	Evolution of HIV-1 transmitted drug resistance in Italy in the 2007â€“2014 period: A weighted analysis. Journal of Clinical Virology, 2018, 106, 49-52.	1.6	8
90	Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. Journal of Clinical Virology, 2018, 104, 61-64.	1.6	19

#	Article	IF	Citations
91	HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. Viruses, 2018, 10, 363.	1.5	4
92	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1â€“4 in Italy. Scientific Reports, 2018, 8, 8988.	1.6	36
93	HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients. PLoS ONE, 2018, 13, e0190302.	1.1	5
94	The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. Journal of Virus Eradication, 2018, 4, 179-181.	0.3	5
95	Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw571.	1.3	3
96	Multiclass <scp>HCV</scp> resistance to directâ€acting antiviral failure in realâ€life patients advocates for tailored secondâ€line therapies. Liver International, 2017, 37, 514-528.	1.9	84
97	Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. Clinical Microbiology and Infection, 2017, 23, 777.e1-777.e4.	2.8	5
98	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Digestive and Liver Disease, 2017, 49, 731-741.	0.4	19
99	Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation. Digestive Diseases and Sciences, 2017, 62, 2193-2195.	1.1	1
100	Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Infection, Genetics and Evolution, 2017, 53, 15-23.	1.0	14
101	HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott Real Time HCV assay. Journal of Virological Methods, 2017, 246, 1-7.	1.0	2
102	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000â€“14. Journal of Antimicrobial Chemotherapy, 2017, 72, 2837-2845.	1.3	15
103	Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. Journal of Antimicrobial Chemotherapy, 2017, 72, 3420-3424.	1.3	10
104	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15
105	Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy. BMC Evolutionary Biology, 2017, 17, 70.	3.2	21
106	Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A realâ€life study. Liver International, 2017, 37, 653-661.	1.9	13
107	Virological response and resistance profile in HIVâ€1â€infected patients starting darunavirâ€containing regimens. HIV Medicine, 2017, 18, 21-32.	1.0	9
108	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS ONE, 2017, 12, e0177352.	1.1	13

#	Article	IF	Citations
109	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS ONE, 2017, 12, e0177402.	1.1	15
110	Sequencing of hepatitis C virus for detection of resistance to directâ€acting antiviral therapy: A systematic review. Hepatology Communications, 2017, 1, 379-390.	2.0	26
111	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS ONE, 2017, 12, e0171611.	1.1	10
112	Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. Oncotarget, 2017, 8, 15704-15715.	0.8	9
113	HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Crosssectional Design. Current HIV Research, 2017, 15, 66-73.	0.2	4
114	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. AIDS Reviews, 2017, 19, .	0.5	5
115	Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 467-473.	0.7	14
116	Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report. Clinical Infectious Diseases, 2016, 64, ciw851.	2.9	3
117	Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw512.	1.3	8
118	The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro. Journal of Global Antimicrobial Resistance, 2016, 7, 1-7.	0.9	3
119	Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. Journal of Clinical Virology, 2016, 82, 94-100.	1.6	35
120	Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Reviews in Medical Virology, 2016, 26, 408-434.	3.9	34
121	Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression. Medicine (United States), 2016, 95, e5222.	0.4	5
122	Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology, 2016, 63, 1058-1059.	3.6	23
123	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 2663-2669.	1.3	10
124	From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease, 2016, 48, 995-1005.	0.4	13
125	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. Journal of Antimicrobial Chemotherapy, 2016, 71, 739-750.	1.3	13
126	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4

#	Article	IF	Citations
127	Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines. AIDS Research and Human Retroviruses, 2016, 32, 329-333.	0.5	4
128	Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. Clinical Microbiology and Infection, 2016, 22, 191-200.	2.8	27
129	Total HIV-1 DNA detection and quantification in peripheral blood by COBASÂ®AmpliPrep/COBASÂ® TaqManÂ® HIV-1 Test, v2.0. Clinical Chemistry and Laboratory Medicine, 2016, 54, e57-9.	1.4	4
130	Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy. PLoS ONE, 2015, 10, e0135325.	1.1	21
131	Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. Digestive and Liver Disease, 2015, 47, 233-241.	0.4	4
132	Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. Digestive and Liver Disease, 2015, 47, 157-163.	0.4	5
133	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European caseâ€“control study using centralized ultrasensitive 454 pyrosequencing. Journal of Antimicrobial Chemotherapy, 2015, 70, 930-940.	1.3	102
134	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Medicine, 2015, 16, 297-306.	1.0	9
135	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. Journal of Clinical Microbiology, 2015, 53, 2935-2941.	1.8	6
136	HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. Journal of Antimicrobial Chemotherapy, 2015, 70, 1865-1873.	1.3	23
137	Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage. Antimicrobial Agents and Chemotherapy, 2015, 59, 4870-4881.	1.4	10
138	Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. Journal of Antimicrobial Chemotherapy, 2015, 70, 3080-3086.	1.3	68
139	Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029. Clinical Microbiology and Infection, 2015, 21, 103.e1-103.e6.	2.8	4
140	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Nonâ€“AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. Journal of Infectious Diseases, 2015, 211, 178-186.	1.9	146
141	Undetectable <scp>HCV</scp>â€<scp>RNA</scp> at treatmentâ€week 8 results in highâ€sustained virological response in <scp>HCV</scp> G1 treatmentâ€experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. Journal of Viral Hepatitis, 2015, 22, 469-480.	1.0	9
142	May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics. New Microbiologica, 2015, 38, 491-7.	0.1	1
143	Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting. Journal of the International AIDS Society, 2014, 17, 19799.	1.2	1
144	Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. Journal of Antimicrobial Chemotherapy, 2014, 69, 2412-2419.	1.3	23

#	Article	IF	Citations
145	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 3085-3094.	1.3	6
146	Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels. Clinical Infectious Diseases, 2014, 58, 1156-1164.	2.9	67
147	Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. BMC Infectious Diseases, 2014, 14, 79.	1.3	23
148	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. Infection, 2014, 42, 61-71.	2.3	7
149	Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors. Antimicrobial Agents and Chemotherapy, 2014, 58, 2781-2797.	1.4	55
150	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 735-741.	1.3	16
151	Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003â€“2012 decade in Italy. BMC Infectious Diseases, 2014, 14, 398.	1.3	13
152	New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. Journal of Antimicrobial Chemotherapy, 2014, 69, 2118-2122.	1.3	50
153	Understanding HIV Compartments and Reservoirs. Current HIV/AIDS Reports, 2014, 11, 186-194.	1.1	66
154	The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature. Journal of Infection, 2014, 69, 408-410.	1.7	2
155	A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-NaÃ¯ve Patients Starting a First-Line HAART. PLoS ONE, 2014, 9, e105853.	1.1	9
156	Drugâ€resistance development differs between <scp>HIV</scp>â€1â€infected patients failing firstâ€line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Medicine, 2013, 14, 571-577.	1.0	7
157	Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. Journal of Infection, 2013, 67, 303-312.	1.7	23
158	Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution. Journal of General Virology, 2013, 94, 143-149.	1.3	28
159	Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. Journal of Antimicrobial Chemotherapy, 2013, 68, 2199-2204.	1.3	7
160	Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. Journal of Antimicrobial Chemotherapy, 2013, 68, 2205-2209.	1.3	8
161	Impact of Pre-Therapy Viral Load on Virological Response to Modern First-Line Haart. Antiviral Therapy, 2013, 18, 867-876.	0.6	34
162	A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based Therapy. Antiviral Therapy, 2013, 18, 1-5.	0.6	18

#	Article	IF	Citations
163	The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing. PLoS ONE, 2013, 8, e53603.	1.1	14
164	Description of the L76V Resistance Protease Mutation in HIV-1 B and â€œNon-Bâ€•Subtypes. PLoS ONE, 2013, 8, e54381.	1.1	1
165	Inhibition of Dual/Mixed Tropic HIV-1 Isolates by CCR5-Inhibitors in Primary Lymphocytes and Macrophages. PLoS ONE, 2013, 8, e68076.	1.1	14
166	Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing. Journal of Infectious Diseases, 2012, 205, 557-567.	1.9	49
167	Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Current Opinion in Infectious Diseases, 2012, 25, 677-686.	1.3	69
168	HIV-Infected Late Presenter Patients. AIDS Research and Treatment, 2012, 2012, 1-2.	0.3	7
169	Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C,) Tj ETQq1 1 0.784314 rgBT	0.5	19
170	Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120V3 signatures in the regulation of co-receptor usage. Virus Research, 2012, 168, 73-83.	1.1	17
171	The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. Clinical Microbiology and Infection, 2012, 18, E289-E298.	2.8	18
172	Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations. Intervirology, 2012, 55, 385-390.	1.2	5
173	Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. Antiviral Research, 2012, 93, 86-93.	1.9	71
174	HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors. PLoS ONE, 2012, 7, e39652.	1.1	78
175	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiologica, 2012, 35, 17-25.	0.1	19
176	Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resistance Updates, 2011, 14, 141-149.	6.5	14
177	Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Digestive and Liver Disease, 2011, 43, 975-983.	0.4	28
178	Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 1481-1483.	1.3	18
179	Identification and Structural Characterization of Novel Genetic Elements in the HIV-1 V3 Loop Regulating Coreceptor Usage. Antiviral Therapy, 2011, 16, 1035-1045.	0.6	23
180	HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Research, 2011, 90, 42-53.	1.9	27

#	Article	IF	Citations
181	Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. Antiviral Research, 2011, 92, 255-261.	1.9	30
182	'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. Journal of Antimicrobial Chemotherapy, 2011, 66, 2615-2623.	1.3	14
183	HIV-2 A-subtype gp125C2-V3-C3 mutations and their association with CCR5 and CXCR4 tropism. Archives of Virology, 2011, 156, 1943-1951.	0.9	7
184	Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120V3signatures in the regulation of Co-Receptor usage. Retrovirology, 2011, 8, 33.	0.9	38
185	Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIVâ€1 Nonâ€nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. ChemMedChem, 2011, 6, 2203-2213.	1.6	14
186	The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. Journal of Antimicrobial Chemotherapy, 2011, 66, 2827-2830.	1.3	43
187	European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Reviews, 2011, 13, 77-108.	0.5	106
188	Is There Any Potential for First-Line Etravirine Use? Analysis From a Large Data Set of Antiretroviral Therapy-Naive HIV-Infected Patients Undergoing Resistance Test. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 150-151.	0.9	0
189	Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin. Antiviral Research, 2010, 88, 124-127.	1.9	6
190	The use of human immunodeficiency virus resistance tests in clinical practice. Clinical Microbiology and Infection, 2010, 16, 1511-1517.	2.8	13
191	Secondary Integrase Resistance Mutations Found in HIV-1 Minority Quasispecies in Integrase Therapy-Naive Patients Have Little or No Effect on Susceptibility to Integrase Inhibitors. Antimicrobial Agents and Chemotherapy, 2010, 54, 3938-3948.	1.4	36
192	Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 336-344.	0.9	32
193	Computational Analysis of Human Immunodeficiency Virus (HIV) Type-1 Reverse Transcriptase Crystallographic Models Based on Significant Conserved Residues Found in Highly Active Antiretroviral Therapy (HAART)-Treated Patients (Supplementary Material). Current Medicinal Chemistry, 2010, 17, 290-308.	1.2	25
194	Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia. Digestive and Liver Disease, 2010, 42, 902-907.	0.4	11
195	Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. Journal of Antimicrobial Chemotherapy, 2010, 65, 2305-2318.	1.3	57
196	Use of novel antiretroviral agents in rescue regimens: A case of early virological failure to raltegravir. Scandinavian Journal of Infectious Diseases, 2010, 42, 237-239.	1.5	1
197	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiologica, 2010, 33, 195-206.	0.1	35
198	Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations in the Human Immunodeficiency Virus Type 1 Regulatory Protein Rev. Antimicrobial Agents and Chemotherapy, 2009, 53, 2816-2823.	1.4	18

#	Article	IF	Citations
199	Effect of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Polymorphism Leu-214 on Replication Capacity and Drug Susceptibility. Journal of Virology, 2009, 83, 7434-7439.	1.5	12
200	Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients. Infection, 2009, 37, 233-243.	2.3	9
201	Effect of Suppressing HIV Viremia on the HIV Progression of Patients Undergoing a Genotype Resistance Test after Treatment Failure. Infection, 2009, 37, 203-209.	2.3	3
202	Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naÃ¯ve to the antiretroviral drugs. BMC Infectious Diseases, 2009, 9, 111.	1.3	23
203	The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. Journal of Hepatology, 2009, 50, 461-470.	1.8	39
204	Molecular Dynamics and Free Energy Studies on the Wild-Type and Mutated HIV-1 Protease Complexed with Four Approved Drugs: Mechanism of Binding and Drug Resistance. Journal of Chemical Information and Modeling, 2009, 49, 1751-1761.	2.5	29
205	Dynamics of NRTI Resistance Mutations during Therapy Interruption. AIDS Research and Human Retroviruses, 2009, 25, 57-64.	0.5	11
206	Resistance to novel drug classes. Current Opinion in HIV and AIDS, 2009, 4, 531-537.	1.5	23
207	Characterization and structural analysis of HIV-1 integrase conservation. AIDS Reviews, 2009, 11, 17-29.	0.5	118
208	Historical resistance profile helps to predict salvage failure. Antiviral Therapy, 2009, 14, 285-291.	0.6	18
209	Short Communication: Characterization of Drug-Resistance Mutations in HIV Type 1 Isolates from Drug-Naive and ARV-Treated Patients in Bulgaria. AIDS Research and Human Retroviruses, 2008, 24, 1133-1138.	0.5	15
210	Specific Enfuvirtideâ€Associated Mutational Pathways in HIVâ€1 Gp41 Are Significantly Correlated With an Increase in CD4+Cell Count, Despite Virological Failure. Journal of Infectious Diseases, 2008, 197, 1408-1418.	1.9	38
211	Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors. Journal of Virology, 2007, 81, 11507-11519.	1.5	62
212	Impact of HIVâ€1 Reverse Transcriptase Polymorphism F214L on Virological Response to Thymidine Analogueâ€"Based Regimens in Antiretroviral Therapy (ART)â€"Naive and ARTâ€Experienced Patients. Journal of Infectious Diseases, 2007, 196, 1180-1190.	1.9	12
213	The V118I Mutation as a Marker of Advanced HIV Infection and Disease Progression. Antiviral Therapy, 2007, 12, 163-168.	0.6	12
214	Virological response to Salvage Therapy in HIV-Infected Persons Carrying the Reverse Transcriptase K65R Mutation. Antiviral Therapy, 2007, 12, 1175-1184.	0.6	22
215	Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir. Journal of Medical Virology, 2006, 78, 535-541.	2.5	14
216	Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors. Journal of Virology, 2006, 80, 7186-7198.	1.5	64

#	Article	IF	Citations
217	Novel drug resistance mutations in HIV: recognition and clinical relevance. AIDS Reviews, 2006, 8, 179-90.	0.5	19
218	Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme. Journal of Medical Virology, 2005, 76, 452-458.	2.5	35
219	The Role of Thr139 in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Sensitivity to (+)-Calanolide A. Molecular Pharmacology, 2005, 68, 652-659.	1.0	15
220	The Amino Acid Asn136 in HIV-1 Reverse Transcriptase (RT) Maintains Efficient Association of Both RT Subunits and Enables the Rational Design of Novel RT Inhibitors. Molecular Pharmacology, 2005, 68, 49-60.	1.0	24
221	Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors. Antimicrobial Agents and Chemotherapy, 2005, 49, 2015-2025.	1.4	58
222	High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations. Journal of Virology, 2005, 79, 10718-10729.	1.5	50
223	Molecular Diversity of HIV in Albania. Journal of Infectious Diseases, 2005, 192, 475-479.	1.9	32
224	Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages. Journal of Antimicrobial Chemotherapy, 2005, 55, 872-878.	1.3	15
225	The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs. FEBS Letters, 2005, 579, 2294-2300.	1.3	23
226	Characterization of Novel HIV Drug Resistance Mutations Using Clustering, Multidimensional Scaling and SVM-Based Feature Ranking. Lecture Notes in Computer Science, 2005, , 285-296.	1.0	18
227	Mutations in HIVâ€1 Reverse Transcriptase Potentially Associated with Hypersusceptibility to Nonnucleoside Reverseâ€Transcriptase Inhibitors: Effect on Response to Efavirenzâ€Based Therapy in an Urban Observational Cohort. Journal of Infectious Diseases, 2004, 189, 1688-1695.	1.9	27
228	Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. Aids, 2004, 18, 11-19.	1.0	52
229	Analysis of nuclear targeting activities of transport signals in the human immunodeficiency virus Rev protein. Experimental Cell Research, 2003, 291, 484-501.	1.2	12
230	Upregulated expression of interleukin-8, RANTES and chemokine receptors in human astrocytic cells infected with HIV-1. Journal of NeuroVirology, 2000, 6, 75-83.	1.0	64
231	Gene transfer in astrocytes: Comparison between different delivering methods and expression of the HIV-1 protein Nef. Journal of Neuroscience Research, 1999, 55, 569-577.	1.3	11
232	Functional characterization of substance P receptors on cultured human spinal cord astrocytes: Synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin E2 production. , 1997, 21, 183-193.		83
233	Cytokineâ€Regulated Expression of Plateletâ€Derived Growth Factor Gene and Protein in Cultured Human Astrocytes. Journal of Neurochemistry, 1996, 66, 1409-1417.	2.1	47